Therapy News and Research

RSS

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.

25 Mar 2015

TVA Medical's novel hemodialysis access technique shows positive outcomes in clinical study

TVA Medical, Inc., today announced promising results from a clinical study evaluating a novel hemodialysis access technique that has the potential to revolutionize vascular access for patients with chronic kidney disease without the use of traditional open surgery.

25 Mar 2015

IV cosyntropin therapy matches EBP in relieving pain from post-dural puncture headache

Intravenous (IV) cosyntropin therapy was equivalent to epidural blood patch (EBP) in relieving pain from post-dural puncture headache (PDPH) with potential for fewer complications and lower costs, data from a randomized, controlled trial showed.

25 Mar 2015

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that it has initiated a Phase 2 trial of its target therapy drug candidate ENMD-2076 in triple-negative breast cancer (TNBC) at the Cancer Hospital of Chinese Academy of Medical Sciences in Beijing, China.

25 Mar 2015

Personalized gene therapy to fight against cancer

The fight to treat cancer and eradicate tumors will likely benefit from a new set of treatments if early development phases continue to show promise, according to Kalorama Information. The healthcare market research publisher stated that gene therapies that are able to deliver genetic material to a specific cell population or tumor that will result in the destruction of the tumor.

25 Mar 2015

Multimodality at the Center for Advanced Biomedical Imaging: an interview with Professor Mark Lythgoe, UCL

Imaging techniques used to live in medical physics departments, where physicists worked on them, but now we're seeing biologists, cell biologists and developmental biologists looking at cellular processes and it's those advances that are really enabling imaging to move forward in a way that it hasn't previously been able to...

From Bruker BioSpin Group 25 Mar 2015

Study: Early improvements not sustained in patients treated with PRP injection for facet joint arthropathy

Early gains in pain relief, behavioral markers and function were not sustained in patients treated with platelet-rich plasma (PRP) injection for facet joint arthropathy, new research shows. Results were available at the 31st Annual Meeting of the American Academy of Pain Medicine.

25 Mar 2015

New approach to treating B-ALL tumour disease

B cell acute lymphoblastic leukaemia, or B-ALL, is the most common tumour disease in children and also occurs in adults. It develops when signalling pathways in immature B cells, or pre-B cells, are dysregulated. Prof. Dr. Markus Müschen from the University of California in San Francisco, USA, and his team worked together with the BIOSS researchers Prof. Dr. Hassan Jumaa and Prof. Dr. Michael Reth to find a new approach for treating the B-ALL tumour disease.

25 Mar 2015

Mesenchymal stem cell transplantation reduces opioid tolerance, opioid-induced pain

Mesenchymal stem cell (MSC) transplantation reduced opioid tolerance and opioid-induced hyperalgesia caused by daily morphine injections in rats, according to new research.

25 Mar 2015

Use of balloon-expandable stent compared with medical therapy increases stroke risk

Among patients with symptomatic intracranial arterial stenosis (narrowing of an artery inside the brain), the use of a balloon-expandable stent compared with medical therapy (clopidogrel and aspirin) resulted in an increased of stroke or transient ischemic attack (TIA), according to a study in the March 24/31 issue of JAMA.

25 Mar 2015

Brain-somatic-activating mutations in MTOR cause focal cortical dysplasia type II

Epilepsy is a brain disorder that afflicts more than 50 million people worldwide. Many epilepsy patients can control their symptoms through medication, but about 30% suffer from intractable epilepsy and are unable to manage the disease with drugs. Intractable epilepsy causes multiple seizures, permanent mental, physical, and developmental disabilities, and even death.

25 Mar 2015

Experimental drug that attacks brain tumor cells passes early tests

An experimental drug that attacks brain tumor tissue by crippling the cells' energy source called the mitochondria has passed early tests in animal models and human tissue cultures, say Houston Methodist scientists.

25 Mar 2015

Boston Scientific announces successful implantations of WATCHMAN Device in three US patients

This week, three patients in the United States received the first implants of the Boston Scientific Corporation WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device.

25 Mar 2015

First randomized, controlled trial of pharmacotherapy in PCD patients now in place

Primary ciliary dyskinesia (PCD) is a rare, genetic respiratory tract disorder leading to progressive pulmonary dysfunction. It exhibits many problems typical for orphan diseases: delayed diagnosis, limited evidence-based knowledge etc. The European Union is funding BESTCILIA (Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia) to introduce uniform guidelines for PCD treatment and diagnosis across Europe.

25 Mar 2015

TB Alliance receives Australian DFAT grant to support late-stage clinical trials of new TB drugs

TB Alliance, a not-for-profit product development partnership with the mission of developing better, faster, and affordable drugs for tuberculosis (TB), has received a grant from the Australian Department of Foreign Affairs and Trade to support late-stage clinical trials of new TB treatments.

25 Mar 2015

Therapy News and Research

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

TVA Medical's novel hemodialysis access technique shows positive outcomes in clinical study

IV cosyntropin therapy matches EBP in relieving pain from post-dural puncture headache

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

Personalized gene therapy to fight against cancer

Multimodality at the Center for Advanced Biomedical Imaging: an interview with Professor Mark Lythgoe, UCL

Study: Early improvements not sustained in patients treated with PRP injection for facet joint arthropathy

New approach to treating B-ALL tumour disease

Mesenchymal stem cell transplantation reduces opioid tolerance, opioid-induced pain

Use of balloon-expandable stent compared with medical therapy increases stroke risk

Brain-somatic-activating mutations in MTOR cause focal cortical dysplasia type II

Experimental drug that attacks brain tumor cells passes early tests

Boston Scientific announces successful implantations of WATCHMAN Device in three US patients

First randomized, controlled trial of pharmacotherapy in PCD patients now in place

TB Alliance receives Australian DFAT grant to support late-stage clinical trials of new TB drugs

Laboratory criteria for CML deep molecular response reviewed

Fourth-line bosutinib ‘appropriate’ after prior CML treatment failure, intolerance

New semi-transparent patch delivers effective treatment for tinnitus

Newly discovered bodily process may explain fetal brain bleeds

Cancer-specific mortality lower in Asian Americans than non-Hispanic whites, shows study

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News